Associations of nerve conduction study variables with clinical symptom scores in patients with type 2 diabetes

다국어 초록 (Multilingual Abstract)

Background: Diabetic peripheral polyneuropathy (DPN) is associated with a variety of symptoms. Nerve conduction studies (NCSs) are considered to be the gold standard of nerve damage assessments, but these studies are often dissociated from the subjective symptoms observed in DPN patients. Thus, the aim of the present study was to investigate the correlations between NCS parameters and neuropathic symptoms quantified using the Michigan Neuropathy Screening Instrument (MNSI).
Methods: Patients with type 2 diabetes mellitus (T2DM) with or without symptoms of neuropathy were retrospectively enrolled. Demographic data, clinical laboratory data, MNSI score, and NCS results were collected for analysis; DPN was diagnosed based on the MNSI score (≥ 3.0) and abnormal NCS results. Pearson’s correlation coefficients were used to evaluate the relationships between MNSI score and NCS variables.
Results: The final analyses included 198 patients (115 men and 83 women) with a mean age of 62.6 ± 12.7 years and a mean duration of diabetes of 12.7 ± 8.4 years. The mean MNSI score was 2.8 (range, 0.0–9.0), and 69 patients (34.8%) were diagnosed with DPN. The MNSI score was positively correlated with the median motor nerve latency and negatively correlated with the median motor, ulnar sensory, peroneal, tibial, and sural nerve conduction velocities (NCVs).
When the patients were categorized into quartiles according to MNSI score, peroneal nerve conduction velocity was significantly lower in the second MNSI quartile than in the first MNSI quartile (p = 0.001). A multivariate analysis revealed that the peroneal NCV was independently associated with MNSI score after adjusting for age, sex, and glycosylated hemoglobin A1c (HbA1c) levels.
Conclusions: The present results indicate that a decrease in peroneal NCV was responsible for early sensory deficits in T2DM patients.

참고문헌 (Reference)

1 Dyck PJ, "The spatial distribution of fiber loss in diabetic polyneuropathy suggests ischemia" 19 : 440-449, 1986

2 Dyck PJ, "The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity" 42 : 1164-1170, 1992

3 Malik RA, "Sural nerve pathology in diabetic patients with minimal but progressive neuropathy" 48 : 578-585, 2005

4 lbers JW, "Subclinical neuropathy among Diabetes Control and Complications Trial participants without diagnosable neuropathy at trial completion: possible predictors of incident neuropathy?" 30 : 2613-2618, 2007

5 Malik RA, "Small fibre neuropathy: role in the diagnosis of diabetic sensorimotor polyneuropathy" 27 : 678-684, 2011

6 Perkins BA, "Simple screening tests for peripheral neuropathy in the diabetes clinic" 24 : 250-256, 2001

7 Kim SS, "Prevalence and clinical implications of painful diabetic peripheral neuropathy in type 2 diabetes: results from a nationwide hospital-based study of diabetic neuropathy in Korea" 103 : 522-529, 2014

8 Won JC, "Prevalence and clinical characteristics of diabetic peripheral neuropathy in hospital patients with type 2 diabetes in Korea" 29 : e290-e296, 2012

9 Binns-Hall O, "One-stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high-risk foot" 35 : 887-894, 2018

10 Albers JW, "Nerve conduction measures in mild diabetic neuropathy in the Early Diabetes Intervention Trial: the effects of age, sex, type of diabetes, disease duration, and anthropometric factors. Tolrestat Study Group for the Early Diabetes Intervention Trial" 46 : 85-91, 1996

11 Dyck PJ, "Monotonicity of nerve tests in diabetes: subclinical nerve dysfunction precedes diagnosis of polyneuropathy" 28 : 2192-2200, 2005

12 Charles M, "Low peripheral nerve conduction velocities and amplitudes are strongly related to diabetic microvascular complications in type 1 diabetes: the EURODIAB Prospective Complications Study" 33 : 2648-2653, 2010

13 Mauer SM, "Long-term study of normal kidneys transplanted into patients with type I diabetes" 38 : 516-523, 1989

14 Tkac I, "Glycemic control is related to the electrophysiologic severity of diabetic peripheral sensorimotor polyneuropathy" 21 : 1749-1752, 1998

15 Baba M, "Electrophysiological changes in diabetic neuropathy:from subclinical alterations to disabling abnormalities" 109 : 234-240, 2001

16 Johnsen B, "Electrodiagnosis of polyneuropathy" 30 : 339-351, 2000

17 England JD, "Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation" 64 : 199-207, 2005

18 Tesfaye S, "Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments" 33 : 2285-2293, 2010

19 "Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group" 10 : 1-19, 1987

20 Dyck PJ, "Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy" 108 (108): 861-880, 1985

21 Caputo GM, "Assessment and management of foot disease in patients with diabetes" 331 : 854-860, 1994

22 Tesfaye S, "Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy" 28 (28): 8-14, 2012

23 Lunetta M, "A simplified diagnostic test for ambulatory screening of peripheral diabetic neuropathy" 39 : 165-172, 1998

24 Feldman EL, "A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy" 17 : 1281-1289, 1994

25 Pastore C, "A comparison of electrophysiological tests for the early diagnosis of diabetic neuropathy" 22 : 1667-1673, 1999